In the last decade, the HIV prevention field has witnessed a
distinct shift, with emphasis on biomedical strategies to
supplement behavioral interventions. One of these approaches is the
use of preexposure prophylaxis (PrEP), co-formulated antiretroviral
medications taken to reduce the risk of HIV infection.
Despite the commonly held belief that marijuana suppresses aggression, many cross-sectional and longitudinal surveys find positive associations between marijuana use and intimate partner violence (IPV).
There are racial disparities in prostate cancer treatment, but
the root causes of these disparities are unknown. Heather Orom,
PhD, is exploring several possible explanations to help reduce
racial gaps in prostate cancer mortality and patient
The prevention of HIV acquisition has been transformed over the
last decade with the introduction of pre-exposure prophylaxis
(PrEP), in which at-risk HIV uninfected individuals take
antiretroviral medications daily to prevent infection.
To maximize its prevention potential, the public health impact
of pre-exposure prophylaxis (PrEP) requires an approach that will
lead to: 1) large-scale adoption among eligible populations and 2)
identification of current gaps among prescribers.